Vivek Subbiah: What a fantastic meeting packed with everything that’s needed for an early-phase drug development program.
Quoting Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, on LinkedIn:
“What a fantastic meeting packed with everything that’s needed for an early-phase drug development program at The 2023 Annual Summit for Evolving Therapies in Oncology: Targeted Therapies, Immunotherapies and Beyond.
Such a delight to co-chair this 2-day multi-stakeholder Drug Development event with Nagla Karim and Alex Spira, organized by Binay Shah and the Binaytara Foundation.
A comprehensive multi-stakeholder meeting with input and fantastic talks from academic and community site investigators, Food and Drug Administration (FDA), National Cancer Institute-Cancer Therapy Evaluation Program (NCI-CTEP), patient advocacy, industry, pharmacy teams, radiology, Artificial Intelligence, nursing, advance practice providers, other clinical trial personnel multidisciplinary teams including cell therapy teams and many more like Stephen Liu, Ludimila Cavalcante, Brian Van Tine and Michael Pishvaian.”
Source: Vivek Subbiah/LinkedIn
